评估提供商和药房对潜在通道阻断剂-循环利尿剂的不一致性 处方级联
Asinamai M Ndai1, Earl J Morris1, Almut G Winterstein1,2
1Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, PO Box 100496, Gainesville, FL, 32610, USA.
Drugs & aging
|January 22, 2024
概括
不一致的供应商和药房增加了处方级联的风险,其中药物的副作用导致新的处方. 这项研究发现,在二皮里丁路阻断-循环利尿剂处方级联中,供应商和药房矛盾的比率更高.
科学领域:
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 处方级联,即药物不良事件导致新的处方,是多药学中的一个重大问题.
- 识别导致这些级联的因素对于制定预防策略至关重要.
研究的目的:
- 调查二皮里丁通道阻断剂 (DHCCB) -循环利尿剂处方级联中不一致的供应商和药房的作用.
- 为了将这种级联与对照二极管 (ACEI/ARB循环利尿剂) 进行比较.
主要方法:
- 使用2011-2018年医疗保险服务费用数据进行的回顾性队列研究.
- 在66岁及以上的成年人中分析了DH CCB循环利尿二和ACEI/ARB循环利尿二.
- 提供商和药房的不一致性被评估为主要结果,倾向性得分对基线特征进行加权.
主要成果:
- 与对照组相比,DH CCB循环利尿剂二显示出更高的提供者异常率 (64%vs. 55%) 和药房异常率 (19%vs. 16%).
- 调整后的分析显示,在DH CCB循环利尿剂级联中,异调提供者的风险增加了20%,药房异调的风险增加了17%.
- 在不和的医疗互动和DH CCB循环利尿剂处方级联之间发现了显著的关联.
结论:
- 不一致的供应商和药房在DHCCB循环的尿剂处方级联中比在对照组中更频繁地参与.
- 这些发现突出了改善护理协调和药物调和的机会.
- 针对护理协调的干预措施可能有助于防止不必要的多药和相关的处方级联.
更多相关视频
相关概念视频
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
836
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
836
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
523
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
523
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
563
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
563
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K